ライフサイエンスコーパス: breast-conserving surgery

1 bserved in stage II BC patients treated with breast conserving surgery.

2 with BC treated with radiotherapy (RT) after breast-conserving surgery.

3 lymph nodes and had completed mastectomy or breast-conserving surgery.

4 with standard whole-breast irradiation after breast-conserving surgery.

5 equencing of TAM and radiotherapy (RT) after breast-conserving surgery.

6 81 to 2.37) were the strongest predictors of breast-conserving surgery.

7 racteristics were associated with the use of breast-conserving surgery.

8 , 60% responded and 48% underwent successful breast-conserving surgery.

9 therapy was given to 86% of patients who had breast-conserving surgery.

10 re twice as likely as other women to undergo breast-conserving surgery.

11 were less likely than other women to undergo breast-conserving surgery.

12 t and transient effect on the rate of use of breast-conserving surgery.

13 All had had breast-conserving surgery.

14 t also influences local recurrence following breast-conserving surgery.

15 ll benefit from neoadjuvant therapy enabling breast-conserving surgery.

16 h in intraoperative margin assessment during breast-conserving surgery.

17 of clinical application of gGlu-HMRG during breast-conserving surgery.

18 The majority of patients (76.1%) underwent breast-conserving surgery.

19 ndular breast tissue is an important step in breast-conserving surgery.

20 e detection of residual cancer tissue during breast-conserving surgery.

21 were submitted for surgery, and 10 underwent breast-conserving surgery.

22 thod for intraoperative margin assessment in breast-conserving surgeries.

23 for potential intraoperative use in guiding breast-conserving surgeries.

24 igher morbidity for mastectomies (4.0%) than breast conserving surgery (1.6%, P < 0.001).

25 and experienced no recurrence, 963 underwent breast-conserving surgery, 263 mastectomy without recons

26 eral invasive breast cancer, 59.6% underwent breast-conserving surgery, 33.4% underwent unilateral ma

27 eral invasive breast cancer, 59.6% underwent breast-conserving surgery, 33.4% underwent unilateral ma

28 After breast-conserving surgery, 90% of local recurrences occu

29 For those who have undergone breast-conserving surgery, a post-treatment mammogram sh

30 For women who have undergone breast-conserving surgery, a post-treatment mammogram sh

31 ined as omissions of radiation therapy after breast-conserving surgery, adjuvant chemotherapy after r

32 st [10.00-12.50 Gy/4-5 fractions]) following breast-conserving surgery administered in community-base

33 ults support the treatment of MO tumors with breast conserving surgery after a detailed clinical eval

34 The impact of tumor biology on the rate of breast-conserving surgery after neoadjuvant chemotherapy

35 gislation, we determined whether the rate of breast-conserving surgery after the legislation was diff

36 an overall survival advantage compared with breast-conserving surgery alone.

37 We examined the trend over time in use of breast-conserving surgery among patients in four sites (

38 surgery in both states and the correlates of breast-conserving surgery among women eligible for the p

39 I, 1.19 to 1.73), but less likely to undergo breast-conserving surgery among women undergoing definit

40 ostoperative whole-breast radiotherapy after breast-conserving surgery and adjuvant endocrine treatme

41 negative breast cancer who were treated with breast-conserving surgery and adjuvant systemic therapy

42 the results of studies of radiotherapy after breast-conserving surgery and after mastectomy, and an i

43 de, and paclitaxel chemotherapy, followed by breast-conserving surgery and axillary lymph node dissec

44 These results support the use of breast-conserving surgery and definitive breast irradiat

45 ng the treatment of DCIS of the breast using breast-conserving surgery and definitive breast irradiat

46 29-83 years (mean, 55.9 years) treated with breast-conserving surgery and irradiation (n = 183) unde

47 erly women have with various providers about breast-conserving surgery and mastectomy.

48 rom 2009 through 2011, to determine rates of breast-conserving surgery and pCR after chemotherapy by

49 ive breast cancers have the highest rates of breast-conserving surgery and pCR after neoadjuvant chem

50 aged 36 or younger at diagnosis treated with breast-conserving surgery and radiation therapy (> or =

51 sociated with LR among patients treated with breast-conserving surgery and radiation therapy.

52 breast cancer patients who were treated with breast-conserving surgery and radiation were analyzed.

53 We compared the outcome of breast-conserving surgery and radiotherapy in BRCA1/2 mu

54 For patients treated with breast-conserving surgery and RT, the 5-year cumulative

55 All 5210 patients underwent breast-conserving surgery and SLN dissection.

56 S treated with vs without the RT boost after breast-conserving surgery and WBRT.

57 , but not both, were permitted), who had had breast-conserving surgery and were receiving adjuvant en

58 658 women who had undergone breast-conserving surgery and who were receiving adjuvan

59 ductal carcinoma in situ (DCIS) treated with breast-conserving surgery and whole-breast irradiation (

60 reported, 20% do not receive radiation after breast-conserving surgery, and 30% to 70% of women with

61 reases the likelihood that women will choose breast-conserving surgery, and enhances patient knowledg

62 osed pure DCIS (no microinvasion), underwent breast-conserving surgery, and received WBRT with or wit

63 ated with older age, total mastectomy versus breast-conserving surgery, and reconstructive surgery.

64 study of persons undergoing cholecystectomy, breast-conserving surgery, anterior cruciate ligament re

65 as minimal mortality, recurrence rates after breast-conserving surgery are significant, and half are

66 Breast conserving surgery (BCS) is a recommended treatme

67 ons exist for early stage breast cancer: (1) breast conserving surgery (BCS), (2) mastectomy with rec

68 regarding NAC, adjuvant chemotherapy (aCT), breast conserving surgery (BCS), bilateral mastectomy (B

69 cancer have a choice between mastectomy and breast conserving surgery (BCS).

70 SL) and wire-guided localization (WGL) after breast conserving surgery (BCS).

71 baseline (n = 124), 44% of patients received breast-conserving surgery (BCS) after anastrozole compar

72 all patients with invasive cancer receiving breast-conserving surgery (BCS) and among patients under

73 ified radical mastectomy (MRM) compared with breast-conserving surgery (BCS) and radiation therapy (R

74 June 1999, demonstrated that tamoxifen after breast-conserving surgery (BCS) and radiotherapy for duc

75 y-stage breast cancer patients, treated with breast-conserving surgery (BCS) and whole-breast irradia

76 tutes of Health Consensus Statement in 1990, breast-conserving surgery (BCS) became more common while

77 lesions may decrease the reoperation rate in breast-conserving surgery (BCS) compared with rates afte

78 tion exists in the use of radiotherapy after breast-conserving surgery (BCS) for ductal carcinoma in

79 quent ipsilateral breast events (IBEs) after breast-conserving surgery (BCS) for ductal carcinoma in

80 aromatase inhibitor (AI) treatment promotes breast-conserving surgery (BCS) for estrogen receptor (E

81 standard for the treatment of DCIS; however, breast-conserving surgery (BCS) has been adopted as the

82 astectomy was performed in 1464 patients and breast-conserving surgery (BCS) in 1395.

83 These 25,000 women included 7300 with breast-conserving surgery (BCS) in trials of radiotherap

84 Radiotherapy (RT) after breast-conserving surgery (BCS) is a standard treatment

85 PURPOSE Breast-conserving surgery (BCS) is an effective treatmen

86 Although breast-conserving surgery (BCS) is often assumed to resu

87 lateral breast tumor recurrence (IBTR) after breast-conserving surgery (BCS) is relatively high.

88 e database for women with DCIS who underwent breast-conserving surgery (BCS) or mastectomy.

89 an expected rates of radiation therapy after breast-conserving surgery (BCS) suggest undertreatment.

90 igh-volume surgeons were more likely to have breast-conserving surgery (BCS) than those managed by lo

91 Guidelines recommend breast-conserving surgery (BCS) with radiation or mastec

92 36; 95% CI, 1.00 to 1.85), and have received breast-conserving surgery (BCS) without radiotherapy (v

93 Strategies were breast-conserving surgery (BCS), BCS with 50-Gy radiatio

94 on in the risk of local recurrence following breast-conserving surgery (BCS), even in "low-risk" popu

95 , and to not receive radiation therapy after breast-conserving surgery (BCS).

96 s unilateral mastectomy (UM), and (3) CPM vs breast-conserving surgery (BCS).

97 e primary treatment option for most women is breast-conserving surgery (BCS).

98 to evaluate residual tumor immediately after breast-conserving surgery (BCS).

99 delivering partial-breast irradiation after breast-conserving surgery (BCS).

100 ologically eligible for either mastectomy or breast-conserving surgery (BCS; n = 125).

101 mor characteristics, treatments (mastectomy, breast-conserving surgery [BCS] with radiation therapy o

102 Breast-conserving surgery combined with axillary lymph n

103 Breast-conserving surgery combined with radiation therap

104 test the benefit of radiotherapy (RT) after breast-conserving surgery compared with observation.

105 wly diagnosed breast cancer who were offered breast-conserving surgery consented from September 2006

106 To ensure successful breast conserving surgeries, efficient tumour margin res

107 cer in a cohort of young women who underwent breast-conserving surgery followed by radiotherapy.

108 ontrol are comparable to outcomes seen after breast-conserving surgery followed by standard whole-bre

109 Radiotherapy (RT) after breast-conserving surgery for early-stage disease has be

110 exists regarding the optimal margin width in breast-conserving surgery for invasive breast cancer.

111 men aged 50 years or older who had undergone breast-conserving surgery for unifocal invasive ductal a

112 rs many women from receiving the benefits of breast-conserving surgery, forcing them to choose a mast

113 pective database of DCIS patients undergoing breast-conserving surgery from 1978 to 2010.

114 At a time when breast-conserving surgery has become more widely used, t

115 Although mastectomy and breast conserving surgery have low risk for complication

116 imately 500 patients treated with APBI after breast-conserving surgery have been published.

117 The rate of breast-conserving surgery in both states and the correla

118 The rate of breast-conserving surgery in both states was much higher

119 the treatment of breast cancer on the use of breast-conserving surgery in clinical practice.

120 Although the rate of breast-conserving surgery in each state was higher than

121 ible for the procedure, nearly 75% underwent breast-conserving surgery in Massachusetts and nearly ha

122 APBI using multicatheter brachytherapy after breast-conserving surgery in patients with early breast

123 In all patients, breast-conserving surgery included complete gross excisi

124 Hypofractionated WBI after breast conserving surgery increased among women with ear

125 proportion of all women who were treated by breast-conserving surgery increased, and because this ap

126 Breast conserving surgery is the preferred treatment for

127 Identifying tumour margins during breast-conserving surgeries is a persistent challenge.

128 Breast-conserving surgery is a more complex treatment th

129 Although breast-conserving surgery is a standard approach for pat

130 arly breast cancer, standard treatment after breast-conserving surgery is adjuvant whole-breast radio

131 Locoregional failure after breast-conserving surgery is associated with increased r

132 The surgical margin status after breast-conserving surgery is considered the strongest pr

133 vention when invasive local recurrence after breast-conserving surgery is detected.

134 st cancer, or ductal carcinoma in situ (when breast-conserving surgery is planned) or are pregnant sh

135 ), inflammatory breast cancer, or DCIS (when breast-conserving surgery is planned) or are pregnant sh

136 e striking fact about local recurrence after breast-conserving surgery is that most occurs in the are

137 ancer after 10 years, but the risk following breast-conserving surgery (lumpectomy) has yet to be det

138 ed who underwent mastectomy (N = 10,471) and breast conserving surgery (N = 16,517).

139 For women who had breast-conserving surgery (n = 49 166), the authors exam

140 Fifty-nine percent of women underwent breast-conserving surgery, of whom 81% received radiatio

141 oportion undergoing an inappropriate form of breast-conserving surgery (omission of radiotherapy, axi

142 rom 30 through 79 years of age who underwent breast-conserving surgery or mastectomy for local or reg

143 decision aid were 25% more likely to choose breast-conserving surgery over mastectomy (risk ratio, 1

144 e were no more likely than others to undergo breast-conserving surgery (P >.2), but these women were

145 m PET (DeltaBF cutoff = -30%; P = 0.03), non-breast-conserving surgery (P = 0.04), and the absence of

146 with lower mortality than that achieved with breast-conserving surgery plus radiation.

147 0,681 hernia, and 0.8% and 0.8% after 42,489 breast-conserving surgery procedures.

148 initive surgical therapy, radiotherapy after breast-conserving surgery, radiation therapy after maste

149 Most women with breast cancer who undergo breast-conserving surgery receive whole-breast irradiati

150 In the randomized trials, radiotherapy after breast-conserving surgery reduced mortality from both br

151 SDI and Medicare coverage had lower rates of breast-conserving surgery than other women (43.2% vs. 49

152 ess likely to undergo standard therapy after breast-conserving surgery than other women.

153 g all surgically treated patients (including breast-conserving surgery), the CPM rate increased by 14

154 to treat DCIS (excluding patients undergoing breast-conserving surgery), the CPM rate increased by 18

155 cancer </= 3 cm were randomly assigned after breast-conserving surgery to 3D-CRT APBI (38.5 Gy in 10

156 ary tumour to avoid mastectomy, and to allow breast-conserving surgery to be done.

157 temporal trends between patients undergoing breast-conserving surgery, unilateral mastectomy, and CP

158 temporal trends between patients undergoing breast-conserving surgery, unilateral mastectomy, and CP

159 without radiation); axillary dissection; and breast-conserving surgery versus mastectomy among women

160 Receipt of breast-conserving surgery versus mastectomy.

161 study of patients undergoing mastectomy and breast conserving surgery was performed from the Nationa

162 the overall rate of radiation therapy after breast-conserving surgery was 80% in the quality improve

163 n the observational data, radiotherapy after breast-conserving surgery was associated with much large

164 Breast-conserving surgery was more frequently performed

165 RT was required if breast-conserving surgery was performed but was elective

166 Breast-conserving surgery was possible in 66.6% of the p

167 Breast-conserving surgery was recommended by surgeons an

168 The rate of breast-conserving surgery was up to 8.7 percent higher t

169 The rates of breast-conserving surgery were 66.7%, 57.9%, and 68.9% i

170 ve and ductal carcinoma in situ treated with breast-conserving surgery were centrally randomised to e

171 invasive ductal breast carcinoma undergoing breast-conserving surgery were enrolled from 28 centres

172 r PgR+) primary breast cancer ineligible for breast-conserving surgery were randomly assigned to 4 mo

173 Rates of breast-conserving surgery were significantly higher in p

174 Rates of breast-conserving surgery were similar between the two g

175 e tumors operable and increases the rates of breast-conserving surgery, while achieving similar long-

176 e, approximately 3% of patients treated with breast-conserving surgery will have an in-breast local r

177 ith stages I or II breast cancer, excised by breast conserving surgery with negative margins, were el

178 ilable published world medical literature on breast-conserving surgery with and without postoperative

179 mastectomy with axillary node dissection or breast-conserving surgery with axillary node dissection

180 situ from patients who had been treated with breast-conserving surgery with or without postoperative

181 Compared with breast-conserving surgery with radiation (10-year mortal

182 agnosed between 1998 and 2007, who underwent breast-conserving surgery with radiation (breast-conserv

183 agnosed between 1998 and 2007, who underwent breast-conserving surgery with radiation (breast-conserv

184 es (95% CI, 1.02 to 1.73) more likely to get breast-conserving surgery with radiation than other type

185 py based on National Guidelines as receiving breast-conserving surgery with radiation therapy and axi

186 and use of definitive surgery (mastectomy or breast-conserving surgery with radiation v breast-conser

187 reported that their surgeon did not discuss breast-conserving surgery with them.

188 gy (ASTRO) guideline on surgical margins for breast-conserving surgery with whole-breast irradiation

189 metastatic SLNs who are planning to undergo breast-conserving surgery with whole-breast radiotherapy

190 e to two metastatic SLNs planning to undergo breast-conserving surgery with whole-breast radiotherapy

191 ductal carcinoma in situ (DCIS) treated with breast-conserving surgery without adjuvant radiation the

192 xols was lower (3.7% vs 5.0%; P < .001), and breast-conserving surgery without other treatment was mo

193 r breast-conserving surgery with radiation v breast-conserving surgery without radiation); axillary d

194 Among women who had breast-conserving surgery, women with SSDI and Medicare